SN
DGX icon

Sittner & Nelson’s Quest Diagnostics DGX Stock Holding History

Sittner & Nelson’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29.4K Hold
150
– – 0.01% 343
2025
Q4 		$28.6K Buy
+150
New +$27.3K 0.01% 313
2021
Q1 		– Sell
-35
Closed -$4K – 410
2020
Q4 		$4K Buy
+35
New +$4.27K ﹤0.01% 331

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Sittner & Nelson's DGX Position: Q1 2026 in Review

Sittner & Nelson held its Quest Diagnostics (DGX) position steady in Q1 2026 at 150 shares worth $29.4K. The position accounts for 0.01% of the portfolio, ranked #343.

Sittner & Nelson first reported a position in DGX in Q4 2020 and has held it in 3 quarters since. 1,063 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Sittner & Nelson held 150 shares of Quest Diagnostics worth $29.4K as of Q1 2026.
  • Sittner & Nelson left its Quest Diagnostics share count unchanged in Q1 2026.
  • Quest Diagnostics made up 0.01% of Sittner & Nelson's portfolio in Q1 2026, its #343 holding.
  • Sittner & Nelson first reported a position in Quest Diagnostics in Q4 2020 and has held it in 3 quarters since.
  • 1,063 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Sittner & Nelson's 13F filing for Q1 2026, filed 12 May 2026.